about
Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonatesEndometrial cell counts in recurrent miscarriage: a comparison of counting methodsDevelopment and inter-rater reliability of the Liverpool adverse drug reaction causality assessment toolEnhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reactionAdverse drug reactions causing admission to a paediatric hospitalIFPA meeting 2008 workshops reportTIPIT: a randomised controlled trial of thyroxine in preterm infants under 28 weeks gestation: magnetic resonance imaging and magnetic resonance angiography protocolIncidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions.Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial.Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?Hospitalised neonates in Estonia commonly receive potentially harmful excipients.Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study.Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital.Randomized controlled trials of antibiotics for neonatal infections: a systematic reviewHuman placental explants in culture: approaches and assessments.Placental phenotypes of intrauterine growth.What can we learn from parents about enhancing participation in pharmacovigilance?Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infectionsPrednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium.Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.Ciprofloxacin use in neonates: a systematic review of the literature.Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development.Which inotrope and when in neonatal and paediatric intensive care?The manipulation of drugs to obtain the required dose: systematic review.Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children.Clinical trials in neonatal sepsis.Aminoglycoside toxicity in neonates: something to worry about?Paediatric drug development: the impact of evolving regulations.Effect of maternal asthma on birthweight and neonatal outcome in a British inner-city population.Gestational age and the C reactive protein responseTASK channel expression in human placenta and cytotrophoblast cells.Secretion of interleukin-1beta and interleukin-6 by fragments of term human placental villi: signalling pathways and effects of tumour necrosis factor alpha and mode of delivery.Oxalate and calcium excretion in cystic fibrosis.Postnatal head growth in preterm infants: a randomized controlled parenteral nutrition study.Toxic excipients in medications for neonates in Brazil.A rapid, reliable method for uNK cell density estimation.GC-MS analysis of ethanol and other volatile compounds in micro-volume blood samples--quantifying neonatal exposure.The regulation of interleukin-6 secretion by prostanoids and members of the tumor necrosis factor superfamily in fresh villous fragments of term human placenta.Toxic additives in medication for preterm infants.CSF cytokine levels in preterm infants may reflect systemic inflammation and are independent of gestation.
P50
Q24619472-4C195A8E-647B-4F45-A47E-C451F47E2D06Q28364768-3A8DFBC8-D6FB-4844-9EBC-09BC677A2445Q28478391-5D8042B0-C40F-48EB-A56E-8C577E22E09CQ28484338-0A2872C7-2E4F-454D-92D0-72F0A4906A64Q28485461-D42DACE6-B018-4AD3-A035-DAA5B5091200Q28754740-8BEF6FA6-F7E9-4265-9105-AC0AE10615E5Q30493913-02C2C293-28FF-4F76-85E7-5051F600EF4AQ31143856-C17B2985-2876-4CEC-9FF8-9EE9691E915AQ33899049-4F431938-0CF8-4896-AB35-B819C02871E2Q34239948-06D2BCAF-2095-4D63-AF30-780B0ADDBD6BQ34397214-038AF4B1-F934-4293-B9C0-68C323AA5039Q34399423-A7EE78F1-5959-435E-8F07-7CA83278AC0DQ34509390-17A9CD10-80C1-46CC-8E57-37B419DB3C52Q34619963-06D44B2C-704F-4AC0-8CBA-BD782801E6A2Q36159671-3BA39725-6684-43E3-80B8-C01C67106E93Q36267751-F8403976-AADC-4E12-A85B-92999BDE433AQ36729977-E14EAB9F-FF08-4D2F-9FAF-A7F068DDF19CQ36754027-864B371D-A0E7-46E4-B550-8E95C5EDFF39Q37448474-74EE8506-635A-4CF9-8346-2973337D3AF1Q37736570-55F30EB0-5336-4D60-9B5D-B05AF16CF495Q37806928-5F4FD36C-C7C2-4678-97B6-842755C54CA3Q37893338-C8A3EC76-9E5A-498F-8DAE-475D18A5F1A2Q37911109-2D153F02-E353-4664-A699-437882A8BB0CQ37973433-C55C97E2-1CC6-40CC-9DAB-26853B2EEC32Q38015811-976053F9-98FC-478D-8028-0A6964A3F43DQ38125671-5E30A389-4FA3-4B50-8987-60DFE45B6280Q38181171-3E02316F-5201-43C3-B130-932B51694ECEQ38189937-0D384D72-AAA0-4D1B-8041-A3439D5ED748Q39786902-EC373C7D-B5D0-4B1C-B7E6-4CD36BB97D01Q42175624-75592BE9-3367-4DCC-8EAF-215D2CF9F697Q42488590-0878BC17-4A64-407B-A5C5-B0DAD068AD7CQ42524067-02BD4381-44AA-4F36-A972-04323F0BD151Q43101613-7060FC6A-1CEE-4951-999E-E79BA9D81A54Q43471063-B4CF6542-D289-47A1-B707-4223447AC29CQ43697329-C88AD75B-1949-44C0-9D3D-440E6ECC85A6Q43727536-F6E71206-6655-4E77-ADD8-CE207B32E099Q44680121-3A9F9021-206F-4213-A35B-9136E1C37263Q44819588-6155FAFA-FE78-4493-9421-4EB0ADB2BDA7Q46154217-312CE34B-7FE8-4877-9E6A-CFA04230E4C5Q46237967-35C29BDA-D3FB-4103-895E-ECFE825D84FD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark A Turner
@nl
Mark A Turner
@sl
Mark A. Turner
@en
Mark A. Turner
@es
type
label
Mark A Turner
@nl
Mark A Turner
@sl
Mark A. Turner
@en
Mark A. Turner
@es
prefLabel
Mark A Turner
@nl
Mark A Turner
@sl
Mark A. Turner
@en
Mark A. Turner
@es
P106
P1153
8968212100
P21
P31
P496
0000-0002-5299-8656